| [March 29, 2018] |
 |
Myelofibrosis Market Spotlight 2018: Key Pipeline and Marketed Drugs, Clinical Trials, Upcoming and Regulatory Events, & Patent Information - ResearchAndMarkets.com
The "Market
Spotlight: Myelofibrosis" report has been added to ResearchAndMarkets.com's
offering.
This Market Spotlight report covers the Myelofibrosis market, comprising
key pipeline and marketed drugs, clinical trials, upcoming and
regulatory events, patent information, a 10-year disease prevalence
forecast, and licensing and acquisition deals, as well as presenting
drug-specific revenue forecasts.
Key Takeaways
-
The author estimates that in 2016, there were 46,000 prevalent cases
of myelofibrosis in adults aged 50 years and older worldwide, and
forecasts that number to increase to 57,000 prevalent cases by 2025.
-
Global prevalence of myelofibrosis is estimated to be 0.0027%.
-
A majority of industry-sponsored drugs in active clinical development
for myelofibrosis are in Phase II. Incyte's Jakafi (ruxolitinib
phosphate) is the only marketed drug for myelofibrosis. It is the
first FDA-approved oral JAK1/2 inhibitor for the treatment of the
disease.
-
Therapies in mid- and late-stage development for myelofibrosis focus
on targets such as JAK/STAT and hedgehog signaling pathways, FMS-like
tyrosine kinase 3, IL-1 receptor-associated kinase 1, histone
deacetylase, telomerase, transfoming growth factor-beta receptor, Src
kinase family, monocytes, interferon receptor, IL-3 receptor, and
BCR-ABL fusion protein. The majority of pipeline drugs in mid- to
late-stage development for myelofibrosis are administered via the oral
route.
-
High-impact upcoming events for drugs in the myelofibrosis space
include pacritinib's topline Phase III trial results and its expected
Committee for Medicinal Products for Human Use (CHMP) opinion.
-
There were only three licensing agreements during 2013-17. The largest
deal during this period was the $1,250m agreement between
Bristol-Myers Squibb and Promedior, pursuant to which Bristol-Myers
Squibb was granted an exclusive right to acquire Promedior along with
its lead asset PRM-151, which is in development for idiopathic
pulmonary fibrosis and myelofibrosis.
-
The clinical trials distribution across Phase I-IV indicates that the
majority of trials for myelofibrosis have been in early and midphases
of development, with 89% of trials in Phase I-II, and only 11% in
Phase III-IV.
-
The US has a substantial lead in the number of myeloproliferative
neoplasm clinical trials globally, yet the forecasted prevalent cases
of myelofibrosis are lower in North America as compared with Asia and
Europe. Germany leads the major EU markets, while South Korea has the
top spot in Asia, where the prevalent cases of myelofibrosis are
highest.
-
Clinical trial activity in the myeloproliferative neoplasms space is
dominated by completed trials. Novartis has the highest number of
completed clinical trials for myeloproliferative neoplasms.
Key Topics Covered:
1 Key Takeaways
2 Disease Background
3 Treatment
4 Epidemiology
5 Marketed Drugs
6 Pipeline Drugs
7 Key Upcoming Events
8 Key Regulatory Events
9 Licensing And Asset Acquisition Deals
10 Parent Patents
11 Revenue Opportunity
12 Clinical Trials Landscape
13 Bibliography
14 Appendix
For more information about this report visit https://www.researchandmarkets.com/research/xkx76b/myelofibrosis?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180329005454/en/
[ Back To TMCnet.com's Homepage ]
|
